Edison Investment Research - Pharmaceuticals & healthcare - Shield Therapeutics: Shield Therapeutics is a UK-based, speciality pharmaceutical company with a primary focus on commercialising its drug Feraccru, which is approved in Europe for the treatment of iron deficiency, with or without anaemia. In this video, healthcare analyst Dr Sean Conroy provides an overview of Shield Therapeutics and outlines the company's strategy for the commercialisation of Feraccru. He finishes the video by detailing Edison’s approach to valuing the company.
See latest research note here.
ISIN: GB00BYV81293
Original Article: Shield Therapeutics (STX) - Executive interview